靶向TROP2在胰腺癌治疗中的潜力

doi:10.19401/j.cnki.1007-3639.2022.03.010

摘要/Abstract

摘要：

胰腺癌是发病率高、进展速度快且生存率低的一种恶性肿瘤,临床上亟待寻找可用于精准治疗或提高预后的新靶标。近年来研究发现,滋养层细胞表面抗原2（trophoblast cell surface antigen 2,TROP2）在多种恶性肿瘤中高表达,通过细胞表面受体信号参与恶性肿瘤细胞的增殖、迁移及黏附等进展过程。概述TROP2在胰腺癌中的表达、参与介导的信号转导通路及以TROP2为靶点的抗肿瘤药物的研究进展,为靶向TROP2在胰腺癌治疗中的机制和提高胰腺癌患者预后方面提供参考。

关键词: 胰腺癌, 滋养层细胞表面抗原2, 靶向治疗, 研究进展

Abstract:

Pancreatic cancer is a malignant tumor with high incidence, rapid progression and low survival rate. It is in urgent need of new targets for precise treatment or improvement of prognosis. In recent years, it has been found that trophoblast cell surface antigen 2 (TROP2) is highly expressed in a variety of malignant tumors and participates in the progress of proliferation, migration and adhesion of malignant tumor cells through cell surface receptor signals. In this paper, the expression of TROP2 in pancreatic cancer, the signaling pathway involved in the mediation of TROP2 and the research progress of antitumor drugs targeting TROP2 were summarized, which provided some references for the mechanism of targeting TROP2 in the treatment of pancreatic cancer and the improvement of prognosis of patients.

Key words: Pancreatic cancer, Trophoblast cell surface antigen 2, Targeted therapy, Research progress

中图分类号:

R735.9

李语婕, 陈颢. 靶向TROP2在胰腺癌治疗中的潜力[J]. 中国癌症杂志, 2022, 32(3): 268-273.

LI Yujie, CHEN Hao. Potential of targeting TROP2 in the treatment of pancreatic cancer[J]. China Oncology, 2022, 32(3): 268-273.

参考文献 42

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.v71.3
[2]	DROUILLARD A, MANFREDI S, LEPAGE C, et al. Epidemiology of pancreatic cancer[J]. Bull Du Cancer, 2018, 105(1): 63-69. doi: 10.1016/j.bulcan.2017.11.004
[3]	GIOVANNETTI E, VAN DER BORDEN C L, FRAMPTON A E, et al. Never let it go: stopping key mechanisms underlying metastasis to fight pancreatic cancer[J]. Semin Cancer Biol, 2017, 44: 43-59. doi: 10.1016/j.semcancer.2017.04.006
[4]	CARIOLI G, MALVEZZI M, BERTUCCIO P, et al. European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer[J]. Ann Oncol, 2021, 32(4): 478-487. doi: 10.1016/j.annonc.2021.01.006
[5]	FERLAY J, PARTENSKY C, BRAY F. More deaths from pancreatic cancer than breast cancer in the EU by 2017[J]. Acta Oncol, 2016, 55(9/10): 1158-1160. doi: 10.1080/0284186X.2016.1197419
[6]	RAHIB L, SMITH B D, AIZENBERG R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States[J]. Cancer Res, 2014, 74(11): 2913-2921. doi: 10.1158/0008-5472.CAN-14-0155
[7]	PERRONE E, MANARA P, LOPEZ S, et al. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo[J]. Mol Oncol, 2020, 14(3): 645-656. doi: 10.1002/mol2.v14.3
[8]	ZAMAN S, JADID H, DENSON A C, et al. Targeting Trop-2 in solid tumors: future prospects[J]. Onco Targets Ther, 2019, 12: 1781-1790. doi: 10.2147/OTT
[9]	LENÁRT S, LENÁRT P, ŠMARDA J, et al. Trop2: jack of all trades, master of none[J]. Cancers (Basel), 2020, 12(11): E3328.
[10]	BARDIA A, MESSERSMITH W A, KIO E A, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase Ⅰ/Ⅱ IMMU-132-01 basket trial[J]. Ann Oncol, 2021, 32(6): 746-756. doi: 10.1016/j.annonc.2021.03.005
[11]	张玉洁, 孙怡琳, 朱苹, 等. 人肿瘤关联钙信号转导因子2的生物信息学分析[J]. 医学研究生学报, 2020, 33(6): 570-576.
	ZHANG Y J, SUN Y L, ZHU P, et al. Bioinformatic analysis of the structure and function of human TACSTD2[J]. J Med Postgrad, 2020, 33(6): 570-576.
[12]	周童, 张远鹏, 张启文. 靶向抑制TROP2基因表达对胰腺癌细胞生物学特性的影响研究[J]. 癌症进展, 2018, 16(3): 290-294.
	ZHOU T, ZHANG Y P, ZHANG Q W. Effect of targeted inhibition of TROP2 gene expression on the biological characteristics of pancreatic cancer cells[J]. Oncol Prog, 2018, 16(3): 290-294.
[13]	CARDILLO T M, GOVINDAN S V, SHARKEY R M, et al. Sacituzumab govitecan (IMMU-132), an anti-trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers[J]. Bioconjug Chem, 2015, 26(5): 919-931. doi: 10.1021/acs.bioconjchem.5b00223
[14]	CUBAS R, ZHANG S, LI M, et al. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway[J]. Mol Cancer, 2010, 9: 253. doi: 10.1186/1476-4598-9-253
[15]	LI X X, TENG S F, ZHANG Y Y, et al. TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT[J]. Oncotarget, 2017, 8(29): 47052-47063. doi: 10.18632/oncotarget.v8i29
[16]	ZHAO W, JIA L, KUAI X, et al. The role and molecular mechanism of Trop2 induced epithelial-mesenchymal transition through mediated β-catenin in gastric cancer[J]. Cancer Med, 2019, 8(3): 1135-1147. doi: 10.1002/cam4.2019.8.issue-3
[17]	GUERRA E, TREROTOLA M, RELLI V, et al. Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer[J]. Neoplasia, 2021, 23(9): 898-911. doi: 10.1016/j.neo.2021.07.002
[18]	SUN X T, XING G Y, ZHANG C, et al. Knockdown of Trop2 inhibits proliferation and migration and induces apoptosis of endometrial cancer cells via AKT/β-catenin pathway[J]. Cell Biochem Funct, 2020, 38(2): 141-148. doi: 10.1002/cbf.v38.2
[19]	ZHAO W, KUAI X W, ZHOU X Y, et al. Trop2 is a potential biomarker for the promotion of EMT in human breast cancer[J]. Oncol Rep, 2018, 40(2): 759-766.
[20]	LIU T, LIU Y Y, BAO X X, et al. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway[J]. PLoS One, 2013, 8(9): e75864. doi: 10.1371/journal.pone.0075864
[21]	GUAN H Y, GUO Z J, LIANG W W, et al. Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways[J]. BMC Cancer, 2017, 17(1): 486. doi: 10.1186/s12885-017-3475-2
[22]	HOU J B, LV A, DENG Q, et al. TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3 signaling pathway[J]. Oncol Rep, 2019, 41(2): 753-764.
[23]	TANG G X, TANG Q, JIA L Z, et al. TROP2 increases growth and metastasis of human oral squamous cell carcinoma through activation of the PI3K/AKT signaling pathway[J]. Int J Mol Med, 2019, 44(6): 2161-2170.
[24]	仇金荣, 唐奇, 林红, 等. 人滋养层细胞表面抗原2在人胰腺癌中的表达及其临床意义[J]. 中华医学杂志, 2011, 91(2): 103-106.
	QIU J R, TANG Q, LIN H, et al. Expression and clinical significance of Trop-2 in human pancreatic cancer[J]. Natl Med J China, 2011, 91(2): 103-106.
[25]	FONG D, MOSER P, KRAMMEL C, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer[J]. Br J Cancer, 2008, 99(8): 1290-1295. doi: 10.1038/sj.bjc.6604677
[26]	SHVARTSUR A, BONAVIDA B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications[J]. Genes Cancer, 2015, 6(3/4): 84-105. doi: 10.18632/genesandcancer.v6i3-4
[27]	MCDOUGALL A R A, TOLCOS M, HOOPER S B, et al. Trop2: from development to disease[J]. Dev Dyn, 2015, 244(2): 99-109. doi: 10.1002/dvdy.v244.2
[28]	MORI Y, AKITA K, OJIMA K, et al. Trophoblast cell surface antigen 2 (Trop-2) phosphorylation by protein kinase C α/δ (PKCα/δ) enhances cell motility[J]. J Biol Chem, 2019, 294(30): 11513-11524. doi: 10.1074/jbc.RA119.008084
[29]	于群, 苗庆芳. 抗肿瘤药物靶点Trop2研究进展[J]. 中国医药生物技术, 2018, 13(4): 353-357.
	YU Q, MIAO Q F. Research progress in antitumor molecular target Trop2[J]. Chin Med Biotechnol, 2018, 13(4): 353-357.
[30]	GUERRA E, TREROTOLA M, TRIPALDI R, et al. Trop-2 induces tumor growth through AKT and determines sensitivity to AKT inhibitors[J]. Clin Cancer Res, 2016, 22(16): 4197-4205. doi: 10.1158/1078-0432.CCR-15-1701
[31]	IKEDA M, YAMAGUCHI M, KATO K, et al. Pr1E11, a novel anti-TROP-2 antibody isolated by adenovirus-based antibody screening, recognizes a unique epitope[J]. Biochem Biophys Res Commun, 2015, 458(4): 877-882. doi: 10.1016/j.bbrc.2015.02.051
[32]	SHARKEY R M, MCBRIDE W J, CARDILLO T M, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-trop-2-SN-38 antibody conjugate (sacituzumab govitecan)[J]. Clin Cancer Res, 2015, 21(22): 5131-5138. doi: 10.1158/1078-0432.CCR-15-0670
[33]	WAHBY S, FASHOYIN-AJE L, OSGOOD C L, et al. FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer[J]. Clin Cancer Res, 2021, 27(7): 1850-1854. doi: 10.1158/1078-0432.CCR-20-3119
[34]	CRISCITIELLO C, MORGANTI S, CURIGLIANO G. Antibody-drug conjugates in solid tumors: a look into novel targets[J]. J Hematol Oncol, 2021, 14(1): 20. doi: 10.1186/s13045-021-01035-z
[35]	BARDIA A, TOLANEY S M, PUNIE K, et al. Biomarker analyses in the phase Ⅲ ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer[J]. Ann Oncol, 2021, 32(9): 1148-1156. doi: 10.1016/j.annonc.2021.06.002
[36]	BARDIA A, HURVITZ S A, TOLANEY S M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16): 1529-1541. doi: 10.1056/NEJMoa2028485
[37]	STROP P, TRAN T T, DORYWALSKA M, et al. RN927C, a site-specific trop-2 antibody-drug conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models[J]. Mol Cancer Ther, 2016, 15(11): 2698-2708. doi: 10.1158/1535-7163.MCT-16-0431
[38]	OKAJIMA D, YASUDA S, MAEJIMA T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells[J]. Mol Cancer Ther, 2021, 20(12): 2329-2340. doi: 10.1158/1535-7163.MCT-21-0206
[39]	MAO Y, WANG X Y, ZHENG F, et al. The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer[J]. Oncotarget, 2016, 7(17): 24810-24823. doi: 10.18632/oncotarget.v7i17
[40]	ROSSI E A, ROSSI D L, CARDILLO T M, et al. Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-α[J]. Mol Cancer Ther, 2014, 13(10): 2341-2351. doi: 10.1158/1535-7163.MCT-14-0345
[41]	CHEN H P, WEI F J, YIN M, et al. CD27 enhances the killing effect of CAR-T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors[J]. Cancer Immunol Immunother, 2021, 70(7): 2059-2071. doi: 10.1007/s00262-020-02838-8
[42]	NISHIMURA T, MITSUNAGA M, SAWADA R, et al. Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody[J]. Cancer Med, 2019, 8(18): 7781-7792. doi: 10.1002/cam4.v8.18